Dvir Dahary

USPTO Granted Patents = 19 (Patent Applications = 14)

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 10.2

ph-index = 7

Forward Citations = 630(Granted Patents)

Company Filing History:

18 out of 60

Compugen Ltd. Corporation

Gavish-galilee Bio Applications Ltd.

patents

where one patent can have more than one assignee

Years Active: 2008-2023

Loading Chart...

19 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11660315 - Universal platform for preparing an inhibitory chimeric antigen receptor (iCAR) (2023-05-30),

2. 8987191 - Bioactive peptides and methods of using same (2015-03-24),

3. 8828940 - Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligands (2014-09-09),

4. 8492329 - Bioactive peptides and methods of using same (2013-07-23),

5. 8349801 - Peptide ligands for G-protein coupled receptors (2013-01-08),

6. 7939634 - Polynucleotides encoding polypeptides and methods using same (2011-05-10),

7. 7906635 - Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer (2011-03-15),

8. 7884180 - Peptides which bind to G protein-coupled receptors (2011-02-08),

9. 7842459 - Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis (2010-11-29),

10. 7745391 - Human thrombospondin polypeptide (2010-06-29),

11. 7714100 - Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of cardiac disease (2010-05-11),

12. 7678769 - Hepatocyte growth factor receptor splice variants and methods of using same (2010-03-16),

13. 7667001 - Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer (2010-02-23),

14. 7655781 - Variants of human glycoprotein hormone alpha chain: compositions and uses thereof (2010-02-02),

15. 7569662 - Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of lung cancer (2009-08-04),

Title: The Innovative Contributions of Dvir Dahary in the Field of Biotechnology

Introduction

Dvir Dahary is a prominent inventor based in Tel Aviv, Israel, known for his significant contributions to biotechnology. With a portfolio of 19 patents, Dvir has been at the forefront of research and innovation, particularly in developing novel therapeutic methods.

Latest Patents

Among his latest inventions is the "Universal platform for preparing an inhibitory chimeric antigen receptor (iCAR)," which is a groundbreaking method aimed at identifying specific targets for iCARs and protective chimeric antigen receptors (pCARs). This invention enables the creation of immune cell therapies that can effectively prevent or reduce undesired immune activation—an important step in cancer treatment. Additionally, he has developed "Bioactive peptides and methods of using the same," which focuses on peptide ligands for G-protein coupled receptors, offering potential therapies for disorders linked to this receptor class.

Career Highlights

Dvir has worked with notable companies such as Compugen Ltd. and Protalix Biotherapeutics, where he has further honed his expertise in biotechnology and innovation. His work has played a critical role in advancing therapeutic applications and pushing the boundaries of current scientific understanding.

Collaborations

Throughout his career, Dvir has collaborated with talented professionals, including Zurit Levine and Amir Toporik. These partnerships have undoubtedly contributed to the development of his innovative products and the success of his research initiatives.

Conclusion

Dvir Dahary's impressive body of work and his commitment to innovation exemplify the spirit of creativity in the field of biotechnology. His patents not only reflect his inventive capabilities but also highlight the potential for transformative therapies in modern medicine. As Dvir continues to explore new directions in his research, the impact of his contributions will likely resonate within the scientific community for years to come.

This text is generated by artificial intelligence and may not be accurate.